RewordedRisk Factors
In January 2025, during the initial days of President Trump's second term, the U.S. announced the imposition government imposed a series of additional substantial tariffs on a broad range of imports from various countries, including China, Canada and Mexico, and the subject countries indicated their intention to impose counter measures. Mexico.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Our internal information technology systems may also fail or experience security breaches, loss or leakage of data, or other disruptions, and the satisfactory performance, reliability and availability of our technology infrastructure is critical to our ability to access data and applications. applications and to operate our business effectively.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
We continue to invest internally in several capacity expansions, if If our acquisition integration efforts, including unlocking synergies, are unsuccessful or if our capacity expansions do not provide the expected returns, we may not realize the full potential of the acquisitions and/or investments and as a result our financial performance may suffer.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is possible that customers may be unable to meet their obligations on a timely basis or may contest their contractual obligations to us under bankruptcy laws or otherwise. otherwise which could adversely affect our ability to collect receivables.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the customer’s pharmaceutical product is not approved by regulatory bodies or it is not successful on the market, the associated costs we may not be recovered. achieve a future return on the time and effort invested in the development of the product.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may not prevail in any such litigation, and if we are unsuccessful, we may not be able to obtain any necessary licenses on reasonable terms or at all. all or such litigation may result in restrictions on our ability to manufacture or sell certain products or operate product lines.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
We expect the market for our products to remain competitive, as consolidation and/or changing of ownership among our competitors and key customers are increasing in the current economic climate. competitive.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, these matters could lead to increased operating costs or interruptions of our normal business operations. operations or could result in restrictions on our ability to manufacture or sell certain products or operate specific product lines.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, Although the continued invasion of Ukraine by Russia has not had a material direct impact to our consolidated results, we have experienced indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions, which could materially adversely affect our results of operations and financial condition.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
If implemented, such Such tariffs and countermeasures could increase have increased the cost of certain raw materials and components used in our packaging solutions, and have the potential to disrupt our global supply chain and create additional operational challenges.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
These specific actions did not have a material affect on our results for 2024, nor do we expect a material effect on our results for 2024 or 2025.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedRisk Factors
Such events Should such an event happen again in the future, it may result in business and manufacturing disruption, inventory shortages due to disruptions to our supply chain and distribution channels, delivery delays, increased risk associated with customer payments, increased labor cost and reduced labor availability, and reduced sales and operations, any of which could materially affect our stock price, business prospects, financial condition, results of operations and liquidity.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If Therefore, if we are unable to collect upon our accounts receivable as they come due in an efficient and timely manner, our business, financial condition or results of operations may be materially adversely affected.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
•Returned $485.8 million to shareholders through share repurchases and dividends
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
•Capital expenditures decreased year over year, ending the year at about 7% of sales
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Net other income increased $25.9 million to $43.1 million in 2025 compared to $17.2 million in 2024. On July 28, 2025, we executed our call option to purchase an additional 31% equity interest in BTY. As a result of this additional investment, we remeasured our previously held minority equity interest in BTY at fair value resulting in a gain of $26.5 million. We also realized approximately $7.3 million in higher equity results from affiliates, which was partially offset by a $2.2 million lower remeasurement gain on our investment in PureCycle.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
The reported effective tax rate for 2025 and 2024 was 20.1% and 20.3%, respectively. The tax rate for 2025 reflects a more favorable mix of earnings including a benefit related to the gain resulting from the remeasurement of equity investments to fair value upon becoming the majority equityholder.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Pharma segment.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Beauty segment.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and other markets form our Closures segment. Our food protection business and elastomeric flow-control technology business report through the Closures segment.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Corporate & Other expenses in 2025 increased slightly to $67.8 million compared to $67.5 million of expense in 2024. Higher compensation costs in 2025 were mostly offset by the improved performance of certain equity method investments and lower costs to evaluate acquisition targets when compared to 2024.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Reconciliation of Adjusted Earnings Per Diluted Share For The Year Ended December 31, 2025 December 31, 2024 Income before Income Taxes $ 491,378 $ 469,765 Adjustments: Restructuring initiatives 9,837 13,002 Curtailment gain related to restructuring initiatives (115) (1,851) Net investment loss (gain) 483 (1,713) Gain from remeasurement of equity method investment (26,518) — Transaction costs related to acquisitions 1,460 140 Purchase accounting adjustments related to acquisitions and investments 1,793 — Other special items 8,360 — Foreign currency effects (1) 14,523 Adjusted Earnings before Income Taxes $ 486,678 $ 493,866 Provision for Income Taxes $ 98,881 $ 95,587 Adjustments: Restructuring initiatives 2,503 3,397 Curtailment gain related to restructuring initiatives (30) (478) Net investment loss (gain) 118 (420) Gain from remeasurement of equity method investment — — Transaction costs related to acquisitions 393 35 Purchase accounting adjustments related to acquisitions and investments 282 — Other special items 2,048 — Foreign currency effects (1) 2,955 Adjusted Provision for Income Taxes $ 104,195 $ 101,076 Net Loss Attributable to Noncontrolling Interests $ 206 $ 363 Net Loss Attributable to Redeemable Noncontrolling Interests $ 86 $ — Net Income Attributable to AptarGroup, Inc. $ 392,789 $ 374,541 Adjustments: Restructuring initiatives 7,334 9,605 Curtailment gain related to restructuring initiatives (85) (1,373) Net investment loss (gain) 365 (1,293) Gain from remeasurement of equity method investment (26,518) — Transaction costs related to acquisitions 1,067 105 Purchase accounting adjustments related to acquisitions and investments 1,511 — Other special items 6,312 — Foreign currency effects (1) 11,568 Adjusted Net Income Attributable to AptarGroup, Inc. $ 382,775 $ 393,153 Average Number of Diluted Shares Outstanding 66,725 67,691 Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 5.89 $ 5.53 Adjustments: Restructuring initiatives 0.11 0.15 Curtailment gain related to restructuring initiatives — (0.02) Net investment loss (gain) 0.01 (0.02) Gain from remeasurement of equity method investment (0.40) — Transaction costs related to acquisitions 0.02 — Purchase accounting adjustments related to acquisitions and investments 0.02 — Other special items 0.09 — Foreign currency effects (1) — 0.17 Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 5.74 $ 5.81
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
On November 20, 2025, we issued $600.0 million in aggregate principal amount of 4.75% Senior Notes due March 2031 in an underwritten public offering. The form and terms of the notes were established pursuant to an Indenture, dated as of March 7, 2022, as amended and supplemented by a Second Supplemental Indenture, dated as of November 20, 2025, each between the Company and U.S. Bank Trust Company, National Association, as trustee. Interest is payable semi-annually in arrears. The notes are unsecured obligations and rank equally in right of payment with our other existing senior, unsecured indebtedness.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
On December 16, 2025, we repaid in full the $125.0 million 3.6% Senior Notes that were due in December 2025.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
AddedMD&A
Management applied judgment in determining the fair value of the acquired assets with respect to the acquisitions of Sommaplast and BTY. The judgments made in determining the estimated fair value assigned to the assets acquired, as well as the estimated life of the assets, can materially impact net income in the periods subsequent to the acquisition through depreciation and amortization. In particular, judgment was applied with respect to determining the fair value of acquired technology, trademarks and customer relationships intangible assets, which involved the use of estimates and significant assumptions with respect to the timing and amounts of cash flow projections, the revenue growth rates, the customer attrition rates, the EBITDA margins and the discount rate. Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RemovedMD&A
A reconciliation of core sales growth to reported net sales growth, the most directly comparable U.S. GAAP measure, can be found under "Net Sales" below.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
•Reported and core sales grew 3%, with annual sales of $3.6 billion, driven by favorable product mix and volume growth
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
•Delivered 30% diluted earnings per share growth and achieved 18% adjusted earnings per share growth
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
Net other income increased $5.9 million to $17.2 million in 2024 compared to $11.2 million in 2023. Interest income increased by $7.7 million due to increased cash flow generated from operations and therefore higher interest earned on cash deposits. This increase, along with the $0.3 million increase due to changes in the fair value of our PureCycle investment, more than compensated for the $2.1 million lower contribution from our equity results from affiliates.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
The reported effective tax rate for 2024 and 2023 was 20.3% and 24.2%, respectively. The tax rate for 2024 was lower compared to 2023 due primarily to the realization of deferred tax assets in Luxembourg which were previously not recognized as well as increased tax benefits from stock-based compensation.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
In thousands, except percentages APTAR CLOSURES SEGMENT Year Ended December 31, 2024 2023 % Change 2024 vs. 2023 Net Sales $ 714,008 $ 698,760 2.2% Adjusted EBITDA (1) 114,142 103,693 10.1 Adjusted EBITDA margin (1) 16.0 % 14.8 %
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
Corporate & Other expenses in 2024 increased to $67.5 million compared to $62.3 million of expense in 2023. Our 2024 results include approximately $2.2 million of foreign currency gains while 2023 includes approximately $4.2 million of realized gains on sales of PCT shares. The remaining cost increases during 2024 include $3.4 million of costs to evaluate potential acquisition targets, along with some higher professional fees for corporate projects and higher incentive compensation costs.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
Management applied judgment in determining the fair value of the acquired assets with respect to the acquisitions of iD SCENT and Gulf Closures, including the fair values of acquired intangibles including acquired technology, trademarks and customer relationships. In particular, judgment was applied with respect to determining the fair value of acquired technology, trademarks and customer relationships intangible assets, which involved the use of benchmarking to prior deals to assess the reasonableness of allocation of excess purchase price to goodwill and intangibles.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
•the execution of our fixed cost reduction initiatives, including our optimization initiative;
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RewordedMD&A
Restructuring initiatives 13,002 589 8,041 3,835 537 9,837 1,080 4,469 3,566 722 Curtailment gain related to restructuring initiatives (1,851) (115) — — (1,851) (115) — Net investment gain loss (1) (1,713) (1,713) 483 483 Gain from remeasurement of equity method investment (26,518) — (26,518) — — Transaction costs related to acquisitions 140 1,460 952 508 — 140 — Purchase accounting adjustments related to acquisitions and investments 1,793 70 1,723 — — Other special items 8,360 8,360 — — — Adjusted earnings before income taxes 479,343 447,942 76,978 56,816 (70,596) (31,797) 486,678 471,535 67,705 59,761 (71,262) (41,061) Interest expense 43,898 43,898 52,737 52,737 Interest income (12,101) (12,101) (11,676) (11,676) Adjusted earnings before net interest and taxes (Adjusted EBIT) 511,140 447,942 76,978 56,816 (70,596) 527,739 471,535 67,705 59,761 (71,262) — Depreciation and amortization 263,784 120,429 82,931 57,326 3,098 287,363 136,111 91,066 56,716 3,470 — Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 774,924 815,102 $ 568,371 607,646 $ 159,909 158,771 $ 114,142 116,477 $ (67,498) (67,792) $ — Reported net income margin (Reported net income / Reported Net Sales) 10.4 % Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.6 % 34.6 35.0 % 13.0 12.1 % 16.0 %
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
During 2024, 2025, we paid $114.1 $120.8 million of dividends, purchased $68.6 $365.0 million of our common stock that was placed into treasury stock stock, received $600.2 million in proceeds from long-term debt obligations, primarily from our note issuance, repaid $166.6 million of long-term debt primarily related to private placement notes and received proceeds of $54.8 $18.9 million on stock option exercises.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2024 2025 Prescription Drug (2) Consumer Health Care Injectables Active Material Science Solutions Digital Health Total Reported Net Sales Growth 15% (3)% 1% 13% 37% 8% (5)% 14% 4% 6% Currency Effects (1) —% (3)% (3)% (3)% (1)% —% —% 1% —% (3)% Acquisitions —% —% —% —% —% —% Core Sales Growth 15% (4)% 1% 13% 38% 8% 5% (8)% 11% 3% 3%
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2024 2025 F&F (2) Personal Care Beauty Home Care Total Reported Net Sales Growth 1% (8)% 10% (3)% 2% 14% 15% 7% Currency Effects (1) (2)% (2)% (1)% (2)% Acquisitions (4)% 1% —% 1% —% Acquisitions —% —% —% —% (13)% (3)% Core Sales Growth (4)% 13% 1% 2% (8)% 11% (3)%
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2024 2025 Consolidated Aptar Aptar Aptar Pharma Beauty Closures Corporate & Other Net Interest Pharma Beauty Closures Net Sales $ 3,582,890 3,777,181 $ 1,643,152 1,737,481 $ 1,225,730 1,309,437 $ 714,008 730,263 $ — $ — Reported net income $ 374,178 392,497 Reported income taxes 95,587 98,881 Reported income before income taxes 469,765 447,353 68,797 54,832 (69,420) (31,797) 491,378 461,073 87,523 56,310 (72,467) (41,061) Adjustments:
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
The positive impact from foreign currency is mainly due to $2.4 million of foreign exchange losses related to the devaluation of the Argentine peso during the fourth quarter of 2023, while the favorable unfavorable impact on pension expense primarily consists of a $1.9 million gain on pension curtailment for a 2024 facility closure in France.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Given our current earnings and anticipated future earnings, we believe that there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to support the realization of $7.0 allow us to reach a conclusion that $1.0 million to $10.0 $5.0 million of deferred tax assets for which there is currently a corresponding the valuation allowance. allowance will no longer be needed.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Cash and equivalents increased to $402.4 million at December 31, 2025 from $223.8 million at December 31, 2024 from $223.6 million at December 31, 2023 while total short and long-term interest bearing debt of $1.48 billion at December 31, 2025 increased from $1.03 billion at December 31, 2024 decreased from $1.14 billion at December 31, 2023. 2024.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2024 Aptar 2025 Pharma Aptar Beauty Aptar Closures Total Reported Net Sales Growth 8% (3)% 6% 7% 2% 3% 5% Currency Effects (1) —% —% 1% —% (3)% (2)% (1)% (2)% Acquisitions —% (3)% —% —% —% (1)% Core Sales Growth 8% (3)% 3% 3% 2% 1% 2%
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2024 2025 Food Beverage Personal Care Other (2) Total Reported Net Sales Growth 4% 3% (4)% 2% 7% (8)% 8% 2% Currency Effects (1) 1% 1% 2% 1% 1% (1)% (1)% (1)% (3)% (1)% Acquisitions —% (1)% —% —% —% —% Core Sales Growth 2% 6% (9)% 5% 3% (2)% 3% 3% 1%
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Optimization initiative $ 9,837 $ 13,019 $ 45,445 Prior year initiatives — (17) (441) Total Restructuring Initiatives $ 9,837 $ 13,002 $ 45,004 Restructuring Initiatives by Segment Aptar Pharma $ 1,080 $ 589 $ 4,852 Aptar Beauty 4,469 8,041 20,683 Aptar Closures 3,566 3,835 17,927 Corporate & Other 722 537 1,542 Total Restructuring Initiatives $ 9,837 $ 13,002 $ 45,004
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
RewordedMD&A
Personal However, personal care core sales increased 2% as 13% over the prior year on higher sales of our hair care and body and skin care products more than compensated for lower sales of our sun care applications. products.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
Quiet changesMD&A
Our determination of fair value involved judgment and the use of significant estimates and significant assumptions, including assumptions regarding the projected revenue growth rates, projected EBITDA margins, as well as the discount rate to calculate estimated future cash flows.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new
Quiet changesMD&A
The allocation of the purchase price utilizes significant estimates and significant assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets.
Read it in 10-K Feb 6, 2026 at sec.govopen_in_new